KALA BIO (KALA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Feb, 2026Opening remarks and agenda
Meeting called to order with confirmation of quorum and agenda overview provided.
Stockholders informed of procedures for submitting questions and voting.
Notice of meeting and proxy materials distributed on December 30, 2025.
Seven agenda items outlined for consideration, with voting instructions given.
Shareholder proposals
Election of three Class II directors to serve until the 2028 annual meeting.
Advisory vote on executive compensation as disclosed in the proxy statement.
Ratification of HCL International LLC as independent auditor for fiscal year ending December 31, 2025.
Authorization for issuance of common stock upon conversion of Series AA and AAA preferred stock.
Amendment to increase authorized common stock from 125 million to 1.5 billion shares.
Authorization for a reverse stock split at a ratio between 1-for-2 and 1-for-100 at board discretion.
Approval for potential adjournment or postponement of the meeting if needed.
Overview of voting outcomes
All director nominees elected by plurality of votes cast.
All proposals, including compensation, auditor ratification, stock issuance, share increase, and reverse split, passed by majority vote.
Adjournment proposal not required as all other items passed.
Latest events from KALA BIO
- Registering 241M+ shares for resale amid Nasdaq compliance risks and leadership changes.KALA
Registration Filing10 Feb 2026 - KPI-012's phase II-B trial for PCED targets a major unmet need, with data expected Q1 2025.KALA
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference2 Feb 2026 - KPI-012 nears phase IIb readout for PCED, targeting broad unmet needs in rare eye diseases.KALA
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - David Lazar's executive experience highlighted as board nomination is updated for the 2025 meeting.KALA
Proxy Filing26 Jan 2026 - Phase IIb trial for a novel secretome therapy in PCED targets broad approval and billion-dollar market.KALA
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Settlements with Baker Bros. and LifeSci increased outstanding shares to 27.8 million.KALA
Proxy Filing6 Jan 2026 - Proxy seeks approval for director elections, share issuance, capital changes, and auditor ratification.KALA
Proxy Filing30 Dec 2025 - Late-stage trial for a stem cell-based eye drop targets broad PCED market with imminent data.KALA
H.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025 - Virtual meeting to vote on directors, compensation, auditor, share issuances, and capital changes.KALA
Proxy Filing19 Dec 2025